-
Je něco špatně v tomto záznamu ?
Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial
ML. Jones, CJ. Martoni, S. Prakash,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
PubMed
23609838
DOI
10.1210/jc.2012-4262
Knihovny.cz E-zdroje
- MeSH
- 25-hydroxyvitamin D 2 krev MeSH
- amidohydrolasy škodlivé účinky metabolismus MeSH
- anticholesteremika škodlivé účinky terapeutické užití MeSH
- bakteriální proteiny škodlivé účinky metabolismus MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- hypercholesterolemie krev dietoterapie MeSH
- intestinální absorpce MeSH
- kalcifediol krev MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- Limosilactobacillus reuteri enzymologie metabolismus MeSH
- mladý dospělý MeSH
- nedostatek vitaminu D etiologie prevence a kontrola MeSH
- probiotika škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- vitamin D metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Česká republika MeSH
CONTEXT: Low serum 25-hydroxyvitamin D is a risk factor for osteoporosis, cardiovascular disease, diabetes, and cancer. Disruption of noncholesterol sterol absorption due to cholesterol-lowering therapies may result in reduced fat-soluble vitamin absorption. OBJECTIVE: We have previously reported on the cholesterol-lowering efficacy and reduced sterol absorption of probiotic bile salt hydrolase active Lactobacillus reuteri NCIMB 30242; however, the effects on fat-soluble vitamins was previously unknown and the objective of the present study. DESIGN, SETTINGS, PATIENTS, AND INTERVENTION: The study was double-blind, placebo-controlled, randomized, parallel-arm, multicenter lasting 13 weeks. A total of 127 otherwise healthy hypercholesterolemic adults with low-density lipoprotein-cholesterol >3.4 mmol/L, triglycerides <4.0 mmol/L, and body mass index of 22 to 32 kg/m² were included. Subjects were recruited from 6 private practices in Prague, Czech Republic, and randomized to consume L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention period. OUTCOME MEASURES: The primary outcome measure was the change in serum low-density lipoprotein-cholesterol over the 9-week intervention. Analysis of fat-soluble vitamins at weeks 0 and 9 were performed post hoc. RESULTS: There were no significant differences between L. reuteri NCIMB 30242 and placebo capsule groups in serum vitamin A, vitamin E, or β-carotene or dietary intake over the intervention period (P > .05). L. reuteri NCIMB 30242 increased serum 25-hydroxyvitamin D by 14.9 nmol/L, or 25.5%, over the intervention period, which was a significant mean change relative to placebo of 17.1 nmol/L, or 22.4%, respectively (P = .003). CONCLUSIONS: To our knowledge, this is the first report of increased circulating 25-hydroxyvitamin D in response to oral probiotic supplementation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20014879
- 003
- CZ-PrNML
- 005
- 20200929120924.0
- 007
- ta
- 008
- 200922s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1210/jc.2012-4262 $2 doi
- 035 __
- $a (PubMed)23609838
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jones, Mitchell L $u Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montreal, Quebec H3A2B4, Canada.
- 245 10
- $a Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial / $c ML. Jones, CJ. Martoni, S. Prakash,
- 520 9_
- $a CONTEXT: Low serum 25-hydroxyvitamin D is a risk factor for osteoporosis, cardiovascular disease, diabetes, and cancer. Disruption of noncholesterol sterol absorption due to cholesterol-lowering therapies may result in reduced fat-soluble vitamin absorption. OBJECTIVE: We have previously reported on the cholesterol-lowering efficacy and reduced sterol absorption of probiotic bile salt hydrolase active Lactobacillus reuteri NCIMB 30242; however, the effects on fat-soluble vitamins was previously unknown and the objective of the present study. DESIGN, SETTINGS, PATIENTS, AND INTERVENTION: The study was double-blind, placebo-controlled, randomized, parallel-arm, multicenter lasting 13 weeks. A total of 127 otherwise healthy hypercholesterolemic adults with low-density lipoprotein-cholesterol >3.4 mmol/L, triglycerides <4.0 mmol/L, and body mass index of 22 to 32 kg/m² were included. Subjects were recruited from 6 private practices in Prague, Czech Republic, and randomized to consume L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention period. OUTCOME MEASURES: The primary outcome measure was the change in serum low-density lipoprotein-cholesterol over the 9-week intervention. Analysis of fat-soluble vitamins at weeks 0 and 9 were performed post hoc. RESULTS: There were no significant differences between L. reuteri NCIMB 30242 and placebo capsule groups in serum vitamin A, vitamin E, or β-carotene or dietary intake over the intervention period (P > .05). L. reuteri NCIMB 30242 increased serum 25-hydroxyvitamin D by 14.9 nmol/L, or 25.5%, over the intervention period, which was a significant mean change relative to placebo of 17.1 nmol/L, or 22.4%, respectively (P = .003). CONCLUSIONS: To our knowledge, this is the first report of increased circulating 25-hydroxyvitamin D in response to oral probiotic supplementation.
- 650 _2
- $a 25-hydroxyvitamin D 2 $x krev $7 D015652
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a amidohydrolasy $x škodlivé účinky $x metabolismus $7 D000581
- 650 _2
- $a anticholesteremika $x škodlivé účinky $x terapeutické užití $7 D000924
- 650 _2
- $a bakteriální proteiny $x škodlivé účinky $x metabolismus $7 D001426
- 650 _2
- $a kalcifediol $x krev $7 D002112
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypercholesterolemie $x krev $x dietoterapie $7 D006937
- 650 _2
- $a intestinální absorpce $7 D007408
- 650 _2
- $a Limosilactobacillus reuteri $x enzymologie $x metabolismus $7 D052200
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a probiotika $x škodlivé účinky $x terapeutické užití $7 D019936
- 650 _2
- $a vitamin D $x metabolismus $7 D014807
- 650 _2
- $a nedostatek vitaminu D $x etiologie $x prevence a kontrola $7 D014808
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Martoni, Christopher J
- 700 1_
- $a Prakash, Satya
- 773 0_
- $w MED00002582 $t The Journal of clinical endocrinology and metabolism $x 1945-7197 $g Roč. 98, č. 7 (2013), s. 2944-2951
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23609838 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200922 $b ABA008
- 991 __
- $a 20200929120920 $b ABA008
- 999 __
- $a ok $b bmc $g 1567739 $s 1105039
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 98 $c 7 $d 2944-2951 $e 20130422 $i 1945-7197 $m The Journal of clinical endocrinology and metabolism $n J Clin Endocrinol Metab $x MED00002582
- LZP __
- $a Pubmed-20200922